Projet MIRACLE (Horizon Europe, appel à projets 2023)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

An estimated 300,000 new cases of leukemia are diagnosed each year globally. The most common form of acute leukemia is acute myeloid leukemia (AML), which is generally a disease of the elderly, while acute lymphoid leukemia (ALL) is most prevalent in children. The biggest problem associated with leukemia treatment is persistence of residual therapy-resistant cancer cells, called minimal residual disease (MRD). MRD can latently persist in the patient for many months, and in response to unknown signals can reawaken and initiate a relapse, which is difficult to treat and responsible for the low survival rates of patients. Currently, knowledge on mechanisms responsible for persistence of MRD and initiation of leukemia relapse is lacking, making development of therapeutics eradicating MRD difficult and hampering improvement of patient cure rates. MIRACLE aims at eradication of MRD and development of clinically efficient treatment strategies that can deliver long-lasting benefit to patients by training a new generation of researchers. MIRACLE will elucidate the leukemia MRD landscape by integrating the knowledge on mechanisms driving persistence of MRD from different angles, and by the subsequent design of efficient and less toxic, novel targeted combination therapy with increased capacity to induce deep responses in patients. With its multidisciplinary team of scientists from academia and industry MIRACLE aims to educate a new generation of researchers optimally equipped to advance and accelerate development of novel therapeutics directed to MRD, and to progress effective treatments to the clinic. The researchers within MIRACLE will be trained to obtain a unique combination of skills in innovative high-tech technologies, advanced data analysis tools and artificial intelligence, organ-on-chip MRD models, and drug and immunotherapy testing, and will come with innovative ideas to advance future leukemia treatment by integration of several disciplines and data sources.

Mots clés : leukemia, minimal residual disease, multi omics, immunotherapy, organ on chip

Participants :
- Université Charles de Prague (Rép. Tchèque) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 237038.4 €
- Stichting proefdiervrij* dutch society for the replacement of animal testing (Pays-Bas) — Partner, associated partner, Autres, subvention : 0.0 €
- Université Vie-Santé Saint-Raphaël (Italie) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Stichting hematon (Pays-Bas) — Partner, associated partner, Autres, subvention : 0.0 €
- Vlaams Instituut voor Biotechnologie (Belgique) — Partner, beneficiary, Recherche, subvention : 262620.0 €
- Université de Cambridge (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Istituti di Ricovero e Cura a Carattere Scientifico (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 259437.6 €
- Université Louis-et-Maximilien de Munich (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 260539.2 €
- Université Johann Wolfgang Goethe de Francfort-sur-le-Main (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 260539.2 €
- Somersault18:24 (Belgique) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University Hospital Frankfurt (Allemagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Active motif (Belgique) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université de Séville (Espagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 251971.2 €
- Mimetas (Netherlands) (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 274370.4 €
- Fundament subsidieadvies (Pays-Bas) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- ORTEC (Netherlands) (Pays-Bas) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université libre d'Amsterdam (Pays-Bas) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Amsterdam University Medical Centers (Pays-Bas) — Coordinator, beneficiary, Recherche, subvention : 548740.8 €
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 282693.6 €
- Université de Salamanque (Espagne) — Partner, associated partner, Organismes publics (hors enseignement & recherche), subvention : 0.0 €
- KU Leuven (Belgique) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Brain & body company (Pays-Bas) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €